Takeda reports strong FY 2016 & more: 4 GI companies making waves

Here are four updates on GI companies from the past week.

Analysts have refuted Citron Research's report on Exact Science's Cologuard, which stated the product was a "seriously inferior product and a disastrous business model." Despite the report causing Exact Science's stock to drop 8 percent, analysts still recommend the stock.

Synthetic Biologics' C. difficile drug, ribaxamase, achieved its primary endpoint in a phase 2b trial. The drug significantly reduces C. difficile infection.

Check-Cap and GE Healthcare achieved their first development milestone when GE's developed and tested X-rays passed all tests to ensure C-scan system compliance. The companies are working to develop an ingestible capsule that will allow preparation-free colorectal cancer screening.

Takeda Pharmaceuticals' gastroenterology, oncology and emerging market platforms increased growth by 14.7 percent in fiscal year 2016.

More articles on gastroenterology:
Harrisburg Gastroenterology victim to data breach — 93k records potentially exposed
IBS patients unsatisfied with treatment for factors beyond physician control — 4 study insights
Tofacitinib effective as induction, maintenance therapy in ulcerative colitis treatment — 6 key notes

© Copyright ASC COMMUNICATIONS 2019. Interested in LINKING to or REPRINTING this content? View our policies by clicking here.

 

Top 40 Articles from the Past 6 Months